Research Correspondence

DOI: 10.4244/EIJ-D-23-00703

Impact of percutaneous mitral paravalvular leak closure on the natural history of recurrent gastrointestinal bleeding

Yassin Belahnech1, MD; Bruno García Del Blanco1,2, MD, PhD; Ignacio Ferreira-González1,3, MD, PhD; Eduard Ródenas-Alesina1, MD; Carmen Alonso-Cotoner4,5, MD; Laura Galian-Gay1,2, MD, PhD; María Bermudez-Ramos4, MD; Rosa Vila-Olives1, MD; Gerard Martí-Aguasca1, MD

Valvular heart disease and gastrointestinal bleeding (GIB) due to angiodysplasia have a well-established link with aortic stenosis, where GIB is believed to be mediated by increased shear stress and acquired von Willebrand (VW) syndrome12. Platelet dysfunction and VW factor abnormalities are less commonly described in mitral regurgitation3 and in dysfunctional valve prostheses4. In these cases, valve replacement frequently solves abnormalities in primary haemostasis14. Little is known about the relationship between mitral paravalvular leaks (PVL) and GIB due to angiodysplasia and whether PVL closure affects the natural history of GIB in these patients. We hypothesised that high velocity jets through the PVL orifice could induce gastrointestinal bleeding due to intestinal angiodysplasia that may otherwise improve if PVL closure is achieved (Figure 1A).

To assess the relationship between PVL and GIB, we included in our study all percutaneous closures of mitral PVL performed in symptomatic patients at a tertiary referral centre between January 2010 and November 2022. Follow-up was completed in May 2023. Redo procedures were not included. To assess the impact of procedural success in recurrent GIB, patients were divided into two groups based on the transoesophageal echocardiographic result of PVL closure. Procedural success was defined as a residual PVL ≤mild. Recurrent GIB was defined as two or more episodes of GIB causing a decrease in haemoglobin ≥2 g/dl or GIB requiring a transfusion of ≥2 units of red blood cells, and it was analysed separately, both before and after percutaneous mitral PVL closure. Fisher’s exact test was used to compare the rates of patients with recurrent bleeding according to procedural success. The study was approved by the local institutional review board (PR[AG]635/2021).

During the study period, 96 patients underwent percutaneous closure of mitral PVL (Central illustration). The median age of patients was 73 (interquartile range [IQR] 66-78) years, and 51 patients (53.1%) were female. The main indications for PVL closure included heart failure (HF) in 37 patients (38.5%), haemolysis in 11 (11.5%), and both conditions in 48 (50.0%). All closures were performed on surgically placed prosthetic mitral valves, of which 80 (83.3%) were mechanical, 78 (81.3%) had severe mitral PVL, 39 (40.6%) had multiple defects, and 52 (54.2%) required more than 1 closure device. Almost all patients (97%) were on oral anticoagulants, and 32 (33%) had an estimated glomerular filtration rate <60 ml/min/1.73 m2. During the year preceding PVL closure, 11 (11%) patients had major recurrent GIB, with angiodysplasia diagnosed in 10 of them. There were no significant differences in terms of the severity or the presence of multiple leaks, nor in terms of anticoagulant treatment between patients with or without GIB before PVL closure. Among these 11 patients, PVL closure was successful in 6 patients, while the other 5 patients continued to experience residual PVL >mild. Procedural success in these patients was associated with lower rates of recurrent GIB (0% vs 80%; p=0.015); thus, none of the patients in whom PVL closure was successful experienced recurrent GIB. In contrast, 4 of the 5 patients whose procedure had failed subsequently developed recurrent GIB during the follow-up period; the fifth patient died shortly after the intervention due to refractory heart failure. The median time to the first GIB was 3 (IQR 1-19) months, and patients had a median of 3 GIB episodes during the follow-up period. GIB-related death occurred in 3 of the 5 patients with unsuccessful PVL closure (Figure 1B). Overall, recurrent GIB after PVL closure was observed in 7 out of 96 patients (7.2%). The mean follow-up period was 3.5±3.3 years. Of the 7 patients with recurrent GIB after PVL closure, 3 had not previously experienced GIB. Of these 7 patients, all (100%) had a residual leak >mild, while procedural failure was observed in 43% of those without recurrent GIB (p=0.004). Overall, there were 14 patients with recurrent GIB either before or after PVL closure, and angiodysplasia was confirmed in 12 (86%) of them using upper and lower endoscopy (all patients) and capsule endoscopy (n=9 patients).

There are some noteworthy considerations that arise from this study. First, the proportion of angiodysplasia in patients with recurrent GIB and PVL (86% in our study) is notably higher than the 5-10% reported in an all-comers study5, suggesting a potential relationship between the two conditions. Second, the significant association between procedural failure and GIB relapse suggests that patients with recurrent GIB related to intestinal angiodysplasia may benefit from PVL closure, aside from the benefits in terms of haemolysis or HF. Lastly, unsuccessful PVL closure may favour the onset of de novo recurrent GIB.

Several limitations of our study, including the retrospective design, small sample size, and potential confounding factors such as anticoagulant therapy, could introduce bias, limit generalisability, and hinder the establishment of causal relationships.

In conclusion, GIB related to angiodysplasia may prompt the evaluation of PVL in carriers of prosthetic mitral valves, as successful PVL closure may resolve GIB episodes. However, further studies are needed to consider recurrent GIB as an indication for mitral PVL closure.

Figure 1. Link between mitral paravalvular leak and gastrointestinal bleeding. A) Potential mechanism linking the presence of mitral paravalvular leak (PVL) and gastrointestinal bleeding (GIB). B) Flowchart of GIB recurrence after mitral percutaneous PVL closure. CV: cardiovascular; GE: gastro-oesophageal; VW: von Willebrand

Central illustration. Recurrence of gastrointestinal bleeding after paravalvular leak closure GIB: gastrointestinal bleeding; PVL: paravalvular leak

Funding

Yassin Belahnech is supported by an unconditional research grant (Rio Hortega [CM22/00242] Instituto de Salud Carlos III and Ajut_AulaVH/2021-01).

Conflict of interest statement

The authors have no conflicts of interest relevant to the contents of this paper to declare.


References

Volume 20 Number 5
Mar 4, 2024
Volume 20 Number 5
View full issue


Key metrics

Trending articles
57.8

State-of-the-Art

10.4244/EIJ-D-24-00386 Feb 3, 2025
Mechanical circulatory support for complex, high-risk percutaneous coronary intervention
Ferro E et al
free
39.45

Clinical research

10.4244/EIJ-D-23-00725 Nov 19, 2023
A systematic algorithm for large-bore arterial access closure after TAVI: the TAVI-MultiCLOSE study
Rosseel L et al
free
39.45

Original Research

10.4244/EIJ-D-23-00725 Mar 18, 2024
A systematic algorithm for large-bore arterial access closure after TAVI: the TAVI-MultiCLOSE study
Rosseel L et al
free
36.35

State-of-the-Art

10.4244/EIJ-D-23-00448 Jan 15, 2024
Coronary spasm and vasomotor dysfunction as a cause of MINOCA
Yaker ZS et al
free
35.15

State-of-the-Art

10.4244/EIJ-D-23-00895 Apr 1, 2024
Percutaneous interventions for pulmonary embolism
Finocchiaro S et al
free
28.5

CLINICAL RESEARCH

10.4244/EIJV11I1A6 May 19, 2015
European expert consensus on rotational atherectomy
Barbato E et al
free
22.55

CLINICAL RESEARCH

10.4244/EIJV12I5A93 Aug 5, 2016
Longer pre-hospital delays and higher mortality in women with STEMI: the e-MUST Registry
Benamer H et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved